LOS ANGELES, August 28, 2024 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, highlights a class action lawsuit against MacroGenics, Inc. (“MacroGenics” or “the Company”) MGNX for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who acquired the Company’s securities during the period of March 7, 2024, to May 9, 2024, inclusive (the “Class Period”), are urged to reach out to the firm before September 24, 2024.
If you are a shareholder who experienced a loss, participate by clicking here.
The firm also suggests contacting Brian Schall of the Schall Law Firm, in Los Angeles, to discuss your rights at no cost. You can reach the firm through www.schallfirm.com or via email at bschall@schallfirm.com.
The class is not yet certified, and until that occurs, you are not represented by an attorney. You can choose to remain an absent class member if you do not take any action.
The Complaint alleges that the Company disseminated false and misleading information to the market. MacroGenics consistently promoted the early interim safety data from the TAMARACK Phase 2 study. The truth surfaced on May 9 when the Company disclosed updated safety and efficacy data for its cancer treatment study TAMARACK. Consequently, the Company’s public statements were deceitful and significantly misguiding throughout the class period. As the market learned the reality about MacroGenics, investors incurred losses.
To recover your losses, consider joining the case.
The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors worldwide.
Please note that this press release may be deemed Attorney Advertising in certain jurisdictions under applicable laws and ethics rules.
CONTACT:
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com
View original content to download multimedia:
https://www.prnewswire.com/news-releases/mgnx-investors-have-opportunity-to-lead-macrogenics-inc-securities-fraud-lawsuit-with-the-schall-law-firm-302232449.html
Source: The Schall Law Firm
